Trial Profile

Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palcitoclax (Primary) ; Ruxolitinib
Indications Myelofibrosis
Focus Adverse reactions; Therapeutic Use
Sponsors Ascentage Pharma

Most Recent Events

31 May 2022 Status changed from recruiting to withdrawn prior to enrolment.
08 Dec 2020 Preliminary results are estimated in October 2022 as per trial design presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2020 Trial design presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com